Embolotherapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Embolotherapy Market Overview

The global embolotherapy market is poised for significant growth, driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders. Embolotherapy, a minimally invasive procedure, is widely used to block blood flow to abnormal tissues, such as tumors or aneurysms, thereby reducing the risk of complications. The market is expected to grow at a compound annual growth rate (CAGR) of 7.5% to 9.2% from 2025 to 2030, reaching a projected market size of $5.8 billion to $6.5 billion by 2030.

Market Size and Share Analysis

In 2025, the embolotherapy market is estimated to be valued at approximately $4.2 billion. By product type, embolic agents hold the largest market share, accounting for 45%-50% of the total market. Embolic coils and liquid embolics are the most widely used products, with embolic coils contributing 30%-35% of the revenue. Among key players, Boston Scientific Corporation, Terumo Medical Systems, and Medtronic dominate the market, collectively holding a share of 40%-45%.

By Product Type

• Embolic Agents: 45%-50% market share
• Embolic Coils: 30%-35% market share
• Liquid Embolics: 15%-20% market share
• Other Products: 5%-10% market share

By Key Players

• Boston Scientific Corporation: 15%-18% market share
• Terumo Medical Systems: 12%-15% market share
• Medtronic: 10%-12% market share
• Johnson & Johnson: 8%-10% market share
• Stryker Corporation: 7%-9% market share
• Other Players: 38%-42% market share

Market Trends

The embolotherapy market is witnessing several key trends:

• Increasing Adoption of Minimally Invasive Procedures: The demand for minimally invasive treatments is rising due to shorter recovery times and reduced hospital stays.
• Technological Advancements: Innovations such as bioresorbable embolic agents and advanced imaging techniques are enhancing the efficacy of embolotherapy.
• Growing Prevalence of Cancer: The rising incidence of cancer, particularly liver and kidney cancers, is driving the demand for embolotherapy.
• Expansion in Emerging Markets: Increasing healthcare infrastructure and awareness in regions like Asia-Pacific and Latin America are contributing to market growth.

Market Segmentation

By Process

• Transcatheter Arterial Embolization (TAE): 40%-45% market share
• Transcatheter Arterial Chemoembolization (TACE): 30%-35% market share
• Radioembolization: 15%-20% market share
• Other Processes: 5%-10% market share

By Application

• Hospitals and Clinics: 60%-65% market share
• Ambulatory Surgical Centers: 25%-30% market share
• Other Applications: 5%-10% market share

By End-Use

• Oncology: 50%-55% market share
• Cardiology: 20%-25% market share
• Neurology: 15%-20% market share
• Other End-Uses: 5%-10% market share

By Region

• North America: 35%-40% market share
• Europe: 25%-30% market share
• Asia-Pacific: 20%-25% market share
• Latin America: 5%-10% market share
• Middle East & Africa: 3%-5% market share

Market News on Policy and Companies

Recent developments in the embolotherapy market include:

• Regulatory Approvals: In 2025, Medtronic received FDA approval for its next-generation embolic coil, enhancing its product portfolio.
• Strategic Collaborations: Boston Scientific Corporation partnered with Sirtex Medical to expand its presence in the radioembolization segment.
• Policy Changes: Governments in emerging markets are increasing funding for cancer treatment, boosting the adoption of embolotherapy.
• Product Launches: Terumo Medical Systems launched a new liquid embolic agent in 2025, targeting the oncology segment.

Segment Forecasts (2025-2030)

The embolotherapy market is expected to witness robust growth across all segments:

• Embolic Agents: CAGR of 8.0%-9.5%
• Embolic Coils: CAGR of 7.0%-8.5%
• Liquid Embolics: CAGR of 9.0%-10.5%
• Transcatheter Arterial Embolization (TAE): CAGR of 7.5%-9.0%
• Hospitals and Clinics: CAGR of 6.5%-8.0%
• Oncology: CAGR of 8.5%-10.0%

Conclusion

The global embolotherapy market is set to experience substantial growth over the forecast period, driven by technological advancements, increasing prevalence of chronic diseases, and expanding healthcare infrastructure in emerging markets. Key players such as Boston Scientific Corporation, Terumo Medical Systems, and Medtronic are expected to maintain their dominance, while new entrants and innovative products will further fuel market expansion. With a projected CAGR of 7.5% to 9.2%, the embolotherapy market represents a lucrative opportunity for stakeholders across the healthcare sector.